RPA-CRISPR/Cas12a检测ALV-J的广谱检测和减少残留扩增子负载

IF 4.5 2区 医学 Q2 CHEMISTRY, MEDICINAL
ACS Infectious Diseases Pub Date : 2026-10-09 Epub Date: 2026-09-28 DOI:10.1021/acsinfecdis.6c00419
Ruiying Han, Ning Xiao, Zhirui Wu, Jiahua Wang, Xiaoli Wang, Xiaochuan Tang
{"title":"RPA-CRISPR/Cas12a检测ALV-J的广谱检测和减少残留扩增子负载","authors":"Ruiying Han,&nbsp;Ning Xiao,&nbsp;Zhirui Wu,&nbsp;Jiahua Wang,&nbsp;Xiaoli Wang,&nbsp;Xiaochuan Tang","doi":"10.1021/acsinfecdis.6c00419","DOIUrl":null,"url":null,"abstract":"<p>Avian leukosis virus subgroup J (ALV-J)\r\nis a retrovirus\r\nthat poses\r\na serious threat to the poultry industry. It is prone to genetic variation,\r\nleading to the emergence of multiple epidemic strains, which creates\r\nsubstantial challenges for clinical detection. Although the recombinase\r\npolymerase amplification (RPA)-CRISPR/Cas12a rapid detection assay\r\ndemonstrates high sensitivity and specificity, it lacks broad applicability\r\nacross multiple viral strains and is susceptible to amplicon contamination.\r\nIn this study, a mixed crRNA-based CRISPR/Cas12a detection system\r\nwas established. Sequence analysis predicts its potential to cover\r\nmost currently circulating ALV-J variant strains. By optimizing the\r\namount of RPA mix and the buffer conditions, a one-tube RPA-CRISPR/Cas12a\r\nassay was developed, with the lowest tested concentration giving 9/9\r\npositive reactions determined to be 1 × 10<sup>0</sup> copies/μL\r\n(equivalent to 15 copies/reaction in a 15 μL reaction). To simplify\r\nthe sample-handling procedure and reduce detection time, a one-pot\r\nRPA-CRISPR/Cas12a assay was established by adding heparin sodium,\r\nachieving the lowest consistently positive concentration of 1 ×\r\n10<sup>2</sup> copies/μL (1500 copies/reaction). Furthermore,\r\nfor lateral flow assay (LFA) that requires exposure to the environment,\r\nthe concentration of amplicons was reduced by restricting RPA amplification\r\nand employing an enhanced Cas12a protein while maintaining a lowest\r\ntested concentration of 1 × 10<sup>1</sup> copies/μL (150\r\ncopies/reaction). Specificity evaluation revealed no cross-reactivity\r\nwith nontarget avian viruses, yielding a positive signal only for\r\nALV-J. When applied to clinical samples, the one-tube RPA-CRISPR/Cas12a\r\nassay exhibited complete agreement with RT-qPCR in terms of positive\r\ndetection rates. The multiple CRISPR/Cas12a-RPA assays developed in\r\nthis study feature broad strain coverage in principle, high accuracy,\r\nand low contamination risk, providing practical tools for rapid ALV-J\r\ndetection across diverse scenarios.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"12 10","pages":"3408–3418"},"PeriodicalIF":4.5000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RPA-CRISPR/Cas12a Assay for ALV-J with Broad-Spectrum Detection and Reduced Residual Amplicon Load\",\"authors\":\"Ruiying Han,&nbsp;Ning Xiao,&nbsp;Zhirui Wu,&nbsp;Jiahua Wang,&nbsp;Xiaoli Wang,&nbsp;Xiaochuan Tang\",\"doi\":\"10.1021/acsinfecdis.6c00419\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Avian leukosis virus subgroup J (ALV-J)\\r\\nis a retrovirus\\r\\nthat poses\\r\\na serious threat to the poultry industry. It is prone to genetic variation,\\r\\nleading to the emergence of multiple epidemic strains, which creates\\r\\nsubstantial challenges for clinical detection. Although the recombinase\\r\\npolymerase amplification (RPA)-CRISPR/Cas12a rapid detection assay\\r\\ndemonstrates high sensitivity and specificity, it lacks broad applicability\\r\\nacross multiple viral strains and is susceptible to amplicon contamination.\\r\\nIn this study, a mixed crRNA-based CRISPR/Cas12a detection system\\r\\nwas established. Sequence analysis predicts its potential to cover\\r\\nmost currently circulating ALV-J variant strains. By optimizing the\\r\\namount of RPA mix and the buffer conditions, a one-tube RPA-CRISPR/Cas12a\\r\\nassay was developed, with the lowest tested concentration giving 9/9\\r\\npositive reactions determined to be 1 × 10<sup>0</sup> copies/μL\\r\\n(equivalent to 15 copies/reaction in a 15 μL reaction). To simplify\\r\\nthe sample-handling procedure and reduce detection time, a one-pot\\r\\nRPA-CRISPR/Cas12a assay was established by adding heparin sodium,\\r\\nachieving the lowest consistently positive concentration of 1 ×\\r\\n10<sup>2</sup> copies/μL (1500 copies/reaction). Furthermore,\\r\\nfor lateral flow assay (LFA) that requires exposure to the environment,\\r\\nthe concentration of amplicons was reduced by restricting RPA amplification\\r\\nand employing an enhanced Cas12a protein while maintaining a lowest\\r\\ntested concentration of 1 × 10<sup>1</sup> copies/μL (150\\r\\ncopies/reaction). Specificity evaluation revealed no cross-reactivity\\r\\nwith nontarget avian viruses, yielding a positive signal only for\\r\\nALV-J. When applied to clinical samples, the one-tube RPA-CRISPR/Cas12a\\r\\nassay exhibited complete agreement with RT-qPCR in terms of positive\\r\\ndetection rates. The multiple CRISPR/Cas12a-RPA assays developed in\\r\\nthis study feature broad strain coverage in principle, high accuracy,\\r\\nand low contamination risk, providing practical tools for rapid ALV-J\\r\\ndetection across diverse scenarios.</p>\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":\"12 10\",\"pages\":\"3408–3418\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2026-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsinfecdis.6c00419\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/9/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.6c00419","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

禽白血病病毒J亚群(ALV-J)是一种严重威胁家禽养殖业的逆转录病毒。它很容易发生遗传变异,导致多种流行菌株的出现,这给临床检测带来了重大挑战。尽管重组聚合酶扩增(RPA)-CRISPR/Cas12a快速检测实验显示出高灵敏度和特异性,但它缺乏跨多种病毒株的广泛适用性,并且容易受到扩增子污染。本研究建立了基于crrna的CRISPR/Cas12a混合检测体系。序列分析预测其可能覆盖目前流行的大多数ALV-J变异株。通过优化RPA混合物的用量和缓冲条件,建立了单管RPA- crispr / cas12a检测方法,确定最低检测浓度为1 × 100 copies/μL(相当于15 μL反应中15 copies/反应),可产生9/9个阳性反应。为了简化样品处理程序,缩短检测时间,通过添加肝素钠建立了单potrpa - crispr /Cas12a检测,最低持续阳性浓度为1 ×102拷贝/μL(1500拷贝/反应)。此外,对于需要暴露于环境中的横向流动试验(LFA),通过限制RPA扩增和使用增强的Cas12a蛋白来降低扩增子的浓度,同时保持最低测试浓度为1 × 101拷贝/μL(150拷贝/反应)。特异性评价显示与非靶禽病毒无交叉反应,仅对alv - j产生阳性信号。当应用于临床样品时,单管RPA-CRISPR/ cas12检测在阳性检出率方面与RT-qPCR完全一致。本研究开发的多种CRISPR/Cas12a-RPA检测方法原则上具有菌株覆盖范围广、准确性高、污染风险低的特点,为在不同情况下快速检测alv - j提供了实用的工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
RPA-CRISPR/Cas12a Assay for ALV-J with Broad-Spectrum Detection and Reduced Residual Amplicon Load

Avian leukosis virus subgroup J (ALV-J) is a retrovirus that poses a serious threat to the poultry industry. It is prone to genetic variation, leading to the emergence of multiple epidemic strains, which creates substantial challenges for clinical detection. Although the recombinase polymerase amplification (RPA)-CRISPR/Cas12a rapid detection assay demonstrates high sensitivity and specificity, it lacks broad applicability across multiple viral strains and is susceptible to amplicon contamination. In this study, a mixed crRNA-based CRISPR/Cas12a detection system was established. Sequence analysis predicts its potential to cover most currently circulating ALV-J variant strains. By optimizing the amount of RPA mix and the buffer conditions, a one-tube RPA-CRISPR/Cas12a assay was developed, with the lowest tested concentration giving 9/9 positive reactions determined to be 1 × 100 copies/μL (equivalent to 15 copies/reaction in a 15 μL reaction). To simplify the sample-handling procedure and reduce detection time, a one-pot RPA-CRISPR/Cas12a assay was established by adding heparin sodium, achieving the lowest consistently positive concentration of 1 × 102 copies/μL (1500 copies/reaction). Furthermore, for lateral flow assay (LFA) that requires exposure to the environment, the concentration of amplicons was reduced by restricting RPA amplification and employing an enhanced Cas12a protein while maintaining a lowest tested concentration of 1 × 101 copies/μL (150 copies/reaction). Specificity evaluation revealed no cross-reactivity with nontarget avian viruses, yielding a positive signal only for ALV-J. When applied to clinical samples, the one-tube RPA-CRISPR/Cas12a assay exhibited complete agreement with RT-qPCR in terms of positive detection rates. The multiple CRISPR/Cas12a-RPA assays developed in this study feature broad strain coverage in principle, high accuracy, and low contamination risk, providing practical tools for rapid ALV-J detection across diverse scenarios.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Infectious Diseases
ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES
CiteScore
9.70
自引率
3.80%
发文量
213
期刊介绍: ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书